Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections

IF 6.8 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Anne Abildtrup Rode, Mahtab Chehri, Laura Rindom Krogsgaard, Kristine Klysner Heno, Anna T?lb?ll Svendsen, Iben Ribberholt, Morten Helms, J?rgen Engberg, Kristian Sch?nning, Michael Tvede, Christian ?stergaard Andersen, Ulrich Stab Jensen, Andreas Munk Petersen, Peter Bytzer
{"title":"Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections","authors":"Anne Abildtrup Rode,&nbsp;Mahtab Chehri,&nbsp;Laura Rindom Krogsgaard,&nbsp;Kristine Klysner Heno,&nbsp;Anna T?lb?ll Svendsen,&nbsp;Iben Ribberholt,&nbsp;Morten Helms,&nbsp;J?rgen Engberg,&nbsp;Kristian Sch?nning,&nbsp;Michael Tvede,&nbsp;Christian ?stergaard Andersen,&nbsp;Ulrich Stab Jensen,&nbsp;Andreas Munk Petersen,&nbsp;Peter Bytzer","doi":"10.1111/apt.16309","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>A defined bacterial mixture could be a safer alternative to faecal microbiota transplantation (FMT).</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>To compare the efficacy of a 12-strain mixture termed rectal bacteriotherapy with either FMT or vancomycin for recurrent <i>Clostridioides difficile</i> infection (CDI) in an open-label 3-arm randomised controlled trial.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We screened all individuals positive for <i>C difficile</i> from May 2017 to March 2019. Persons with laboratory-confirmed recurrent CDI were included. Before FMT and rectal bacteriotherapy, we pre-treated with vancomycin for 7-14 days. Rectal bacteriotherapy was applied by enema on three consecutive days and FMT by enema once with possible repetition for two to three infusions within 14 days. The vancomycin group was treated for 14 days with additional five weeks of tapering for multiple recurrences. The primary outcome was clinical cure within 90 days. A secondary outcome was 180-day all-cause mortality.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Participants in the FMT group (n = 34) were cured more often than participants receiving vancomycin (n = 31), 76% vs 45% (OR 3.9 (1.4-11.4), <i>P</i> &lt; 0.01) or rectal bacteriotherapy (n = 31), 76% vs 52% (OR 3.0 (1.1-8.8), <i>P</i> = 0.04). Rectal bacteriotherapy and vancomycin performed similarly (<i>P</i> = 0.61). The mortality rate was 6% in the FMT group, 13% in the bacteriotherapy group and 23% in the vancomycin group. FMT tended to reduce mortality compared with vancomycin, OR 0.2 (0.04-1.12), <i>P</i> = 0.07.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Rectal bacteriotherapy appears as effective as vancomycin but less effective than 1-3 FMTs. FMT by enema with 1-3 infusions is superior to vancomycin for treating recurrent <i>C difficile</i> infections and might reduce mortality.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"53 9","pages":"999-1009"},"PeriodicalIF":6.8000,"publicationDate":"2021-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"21","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.16309","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 21

Abstract

Background

A defined bacterial mixture could be a safer alternative to faecal microbiota transplantation (FMT).

Aims

To compare the efficacy of a 12-strain mixture termed rectal bacteriotherapy with either FMT or vancomycin for recurrent Clostridioides difficile infection (CDI) in an open-label 3-arm randomised controlled trial.

Methods

We screened all individuals positive for C difficile from May 2017 to March 2019. Persons with laboratory-confirmed recurrent CDI were included. Before FMT and rectal bacteriotherapy, we pre-treated with vancomycin for 7-14 days. Rectal bacteriotherapy was applied by enema on three consecutive days and FMT by enema once with possible repetition for two to three infusions within 14 days. The vancomycin group was treated for 14 days with additional five weeks of tapering for multiple recurrences. The primary outcome was clinical cure within 90 days. A secondary outcome was 180-day all-cause mortality.

Results

Participants in the FMT group (n = 34) were cured more often than participants receiving vancomycin (n = 31), 76% vs 45% (OR 3.9 (1.4-11.4), P < 0.01) or rectal bacteriotherapy (n = 31), 76% vs 52% (OR 3.0 (1.1-8.8), P = 0.04). Rectal bacteriotherapy and vancomycin performed similarly (P = 0.61). The mortality rate was 6% in the FMT group, 13% in the bacteriotherapy group and 23% in the vancomycin group. FMT tended to reduce mortality compared with vancomycin, OR 0.2 (0.04-1.12), P = 0.07.

Conclusions

Rectal bacteriotherapy appears as effective as vancomycin but less effective than 1-3 FMTs. FMT by enema with 1-3 infusions is superior to vancomycin for treating recurrent C difficile infections and might reduce mortality.

Abstract Image

随机临床试验:12株细菌混合物与粪便微生物群移植和万古霉素治疗复发性艰难梭菌感染
明确的细菌混合物可能是粪便微生物群移植(FMT)的一种更安全的替代方法。目的:在一项开放标签三组随机对照试验中,比较12菌株混合物直肠细菌治疗与FMT或万古霉素治疗复发性艰难梭菌感染(CDI)的疗效。方法对2017年5月至2019年3月期间所有艰难梭菌阳性个体进行筛查。实验室确认的复发性CDI患者被纳入研究。在FMT和直肠细菌治疗前,我们用万古霉素预处理7-14天。直肠细菌治疗采用灌肠连续3天,FMT灌肠1次,14天内可能重复2 ~ 3次。万古霉素组治疗14天,多次复发再加5周减量治疗。主要终点为90天内临床治愈。次要终点是180天全因死亡率。结果FMT组(n = 34)的治愈率高于万古霉素组(n = 31),分别为76% vs 45% (OR 3.9 (1.4-11.4), P <0.01)或直肠细菌治疗(n = 31), 76% vs 52% (or 3.0 (1.1-8.8), P = 0.04)。直肠细菌治疗和万古霉素治疗效果相似(P = 0.61)。FMT组死亡率为6%,细菌治疗组为13%,万古霉素组为23%。与万古霉素相比,FMT有降低死亡率的趋势,OR为0.2 (0.04-1.12),P = 0.07。结论直肠细菌治疗效果与万古霉素相当,但不如1-3次FMTs。FMT灌肠1-3次输注优于万古霉素治疗复发性艰难梭菌感染,并可能降低死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书